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Introduction: Matrix detachment triggers anoikis, a form of apoptosis, in most normal epithelial cells, while
acquisition of anoikis resistance is a prime requisite for solid tumor growth. Of note, recent studies have revealed
that a small population of normal human mammary epithelial cells (HMECs) survive in suspension and generate
multicellular spheroids termed ‘mammospheres’. Therefore, understanding how normal HMECs overcome anoikis
may provide insights into breast cancer initiation and progression.
Methods: Primary breast tissue-derived normal HMECs were grown as adherent monolayers or mammospheres.
The status of AMP-activated protein kinase (AMPK) and PEA15 signaling was investigated by immunoblotting.
Pharmacological agents and an RNA interference (RNAi) approach were employed to gauge their roles in
mammosphere formation. Immunoprecipitation and in vitro kinase assays were undertaken to evaluate interactions
between AMPK and PEA15. In vitro sphere formation and tumor xenograft assays were performed to understand
their roles in tumorigenicity.
Results: In this study, we show that mammosphere formation by normal HMECs is accompanied with an increase
in AMPK activity. Inhibition or knockdown of AMPK impaired mammosphere formation. Concomitant with AMPK
activation, we detected increased Ser116 phosphorylation of PEA15, which promotes its anti-apoptotic functions.
Inhibition or knockdown of AMPK impaired PEA15 Ser116 phosphorylation and increased apoptosis. Knockdown of
PEA15, or overexpression of the nonphosphorylatable S116A mutant of PEA15, also abrogated mammosphere
formation. We further demonstrate that AMPK directly interacts with and phosphorylates PEA15 at Ser116 residue,
thus identifying PEA15 as a novel AMPK substrate. Together, these data revealed that AMPK activation facilitates
mammosphere formation by inhibition of apoptosis, at least in part, through Ser116 phosphorylation of PEA15. Since
anoikis resistance plays a critical role in solid tumor growth, we investigated the relevance of these findings in the
context of breast cancer. Significantly, we show that the AMPK-PEA15 axis plays an important role in the
anchorage-independent growth of breast cancer cells both in vitro and in vivo.
Conclusions: Our study identifies a novel AMPK-PEA15 signaling axis in the anchorage-independent growth of
both normal and cancerous mammary epithelial cells, suggesting that breast cancer cells may employ mechanisms
of anoikis resistance already inherent within a subset of normal HMECs. Thus, targeting the AMPK-PEA15 axis might
prevent breast cancer dissemination and metastasis.* Correspondence: anu@mrdg.iisc.ernet.in
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Epithelial cells grow attached to their extracellular matrix
(ECM) composed of collagen, elastins, fibronectin, laminin,
proteoglycans and glycosaminoglycans [1]. Signals emanat-
ing from cell-matrix interactions regulate gene expression,
cell growth and survival [2]. Consequently, matrix with-
drawal triggers a form of apoptosis, termed anoikis, in nor-
mal adherent (ADH) cells [3]. Anoikis plays an important
role during development as well as in the maintenance of
tissue homeostasis in adult life [4]. In contrast, acquisition
of anoikis resistance is a hallmark of epithelial cancer pro-
gression [5].
Untransformed mammary epithelial cells undergo anoi-
kis upon matrix detachment [6]. Intriguingly, recent stud-
ies have demonstrated that a small population of normal
human mammary epithelial cells (HMECs) survive under
anchorage-independent conditions to generate floating
spheroids termed ‘mammospheres’ (MS) when cultured in
ultra-low (UL) attachment plates under serum-free condi-
tions [7,8]. However, the mechanisms that enable this sub-
set of normal HMECs to escape anoikis and survive in
suspension remain unexplored. Acquisition of anoikis re-
sistance is considered to be a prerequisite for solid tumor
metastasis, enabling cancer cells to survive in the circula-
tion [9]. Moreover, in the context of mammary gland, anoi-
kis resistance is thought to be involved in luminal filling
associated with early breast lesions such as ductal carcin-
oma in situ [10]. Therefore, understanding the molecular
mechanisms that enable a subset of normal HMECs to
withstand anoikis and generate MS is likely to provide im-
portant insights into normal mammary gland biology, as
well as breast cancer progression.
The AMP-activated protein kinase (AMPK) is a cellular
energy sensor that is activated under stresses leading to an
increase in the AMP: adenosine triphosphate (ATP) ratio,
such as, nutrient deprivation, hypoxia, oxidative stress and
endoplasmic reticulum (ER) stress [11]. Mammalian AMPK
is a heterotrimeric complex consisting of one catalytic sub-
unit α (63 kDa) and two regulatory subunits β and γ (38
and 36 kDa, respectively); each of these subunits has mul-
tiple isoforms (α1 and α2, β1 and β2, γ1, γ2, and γ3). AMP
binds to the γ subunit of AMPK and brings about its
allosteric activation. Additionally, AMPK is phosphory-
lated at Thr172 within its α subunit by liver kinase B1
(LKB1), Ca2+/calmodulin-dependent protein kinase kinase
(CaMKK) and transforming growth factor-β activated kin-
ase (TAK), and this phosphorylation is essential for its func-
tional activation [11]. Recent reports have highlighted the
importance of AMPK signaling in the survival of both nor-
mal and cancer cells under metabolic stress conditions
[12,13]. We have demonstrated that AMPK activation can
protect cancer cells from glucose deprivation-induced stress
by inducing autophagy [14], an evolutionarily conserved
cellular catabolic process. Recently, AMPK activation hasalso been implicated in anoikis resistance [15-17]. Also, in-
creased levels of phosphorylated (p)AMPK was reported
in MCF10A immortalized mammary epithelial cells sub-
jected to matrix detachment [18], suggesting that AMPK
signaling may be involved in the survival and growth of
HMECs in suspension.
The phosphoprotein enriched in astrocytes 15 kDa/
phosphoprotein enriched in diabetes (PEA15/PED) is a
multifunctional protein highly expressed in astrocytes [19].
PEA15 plays a critical role in restricting extracellular
signal-regulated kinase (ERK) in the cytoplasm [20], thus
functioning as a tumor suppressor. However, recent stud-
ies have shown that phosphorylation leads to a change in
its binding partners and cellular functions [21]. Phosphor-
ylation at its Ser116 position has been shown to promote
its anti-apoptotic functions by binding to Fas-associated
death domain protein (FADD) and preventing the recruit-
ment of initiator caspases [22]. More recently, PEA15
phosphorylated at Ser116 has been shown to protect glioma
cells from glucose deprivation-induced apoptosis [23].
Thus, phosphorylated PEA15 can provide anti-apoptotic
signals under stress conditions.
In this study, we explored the signaling mechanisms that
enable the anoikis-resistant outgrowth of MS. We show
that MS formation is associated with an increase in AMPK
activity, and this activation is essential for sphere forma-
tion. We further show that AMPK facilitates MS forma-
tion by inhibiting apoptosis, at least in part, through
phosphorylation of PEA15 at Ser116 residue. We addition-
ally show that this AMPK-PEA15 signaling axis is also as-
sociated with the anchorage-independent growth of breast
cancer cells in vitro and in vivo, suggesting that cancer
cells may exploit properties inherent within a subset of
normal cells for their survival during matrix-deprived con-
ditions. Thus, our data provides support for the pro-
tumorigenic functions of AMPK, and uncovers a novel
AMPK-PEA15 axis in the anoikis-resistant growth of
mammary epithelial cells.
Methods
Primary HMEC culture and mammosphere formation
Primary breast tissues were procured from Kidwai
Memorial Institute of Oncology (KMIO) Bangalore, India,
as approved by the Medical Ethics Committee (the insti-
tutional review board (IRB) of KMIO) and in compliance
with the ethical guidelines of the Indian Institute of
Science (IISc). Patient consent was obtained in a written
form prior to surgery, as per the protocol approved by the
IRB of KMIO. Primary breast tissue was processed as
described previously [8]. In brief, mechanical followed by
enzymatic processing of normal breast tissue yielded orga-
noids, which were trypsinized and filtered through a 70
μm cell strainer (BD Biosciences, San Jose, CA, USA) to
obtain largely single cells. These freshly derived HMECs
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human epidermal growth factor (hEGF), 1 μg/ml hydro-
cortisone, 10 μg/ml insulin, 4 ng/ml heparin and B27 at a
density of 2 × 105 cells per 2 mL/well of 6-well UL attach-
ment plates (Corning Inc., New York, NY, USA). Under
these conditions primary MS were formed within a week.
To compare signaling in adherent versus suspension
conditions, freshly derived HMECs were typically seeded
in parallel in conventional 9 cm tissue culture plates for
adherent (ADH) culture or in 6-well UL attachment
plates for MS formation (Figure 1). Cells were harvested
at the end of seven days for further experimentation, or
as indicated (Figure 1). Total numbers of spheres formed
were counted at the end of seven days under a micro-
scope as described previously [8].
Western blotting and immunoprecipitation
Whole cell lysates for western blotting were prepared
with lysis buffer containing 1% NP40 detergent, 0.5% so-
dium deoxycholate, 0.1% SDS, 50 mM sodium fluoride,
1 mM sodium orthovandate, 10 mM sodium pyrophos-
phate (Sigma-Aldrich, St Louis, MO, USA) and protease
inhibitors (Roche, Basel, Switzerland). Protein concen-
tration was estimated with Bradford reagent and equal
amount of protein was resolved by SDS-PAGE using
Bio-Rad apparatus, (Bio-Rad Laboratories, Hercules, CA,
USA) transferred to a PVDF membrane (EMD Millipore,
Merck, Darmstadt, Germany) and probed with appro-
priate antibodies. Horseradish peroxide (HRP)-coupled
secondary antibodies were obtained from The Jackson
Laboratory (Bar Harbor, ME, USA), and immunoblots
were visualized using PICO reagent (Thermo Fisher
Scientific, Waltham, MA, USA). Primary antibodies against
pAMPK, total AMPK, phosphorylated acetyl-Co-A car-
boxylase (pACC), total ACC, pRaptor, total Raptor,
cleaved poly(ADP-ribose) polymerase (PARP), caspase-3
and caspase-8 were purchased from Cell Signaling Tech-
nology (Danvers, MA, USA). The antibodies against total
PEA15 and pPEA15 Ser104 were from Cell Signaling
Technology, while pPEA15 Ser116 was from Thermo
Fisher Scientific. The levels of respective total proteins
was probed and observed to be the same for all western
blots involving phosphoprotein analyses. Anti α-tubulin
(Calbiochem, Merck, Darmstadt, Germany) served as the
loading control in all western blots. Multi-panel blots in a
given figure were assembled by reprobing the same blot.
For densitometry analyses of western blots, band inten-
sities acquired using Image-J were first normalized to
tubulin expression, and the ratio of phosphoprotein rela-
tive to its total protein is represented graphically as fold
change over control condition.
For immunoprecipitation (IP) assays, cells were lysed
with co-IP lysis buffer (Pierce co-IP Kit 26149; Thermo
Fisher Scientific). One milligram of total proteins wascleared with control agarose resin for 1 hr at 4°C. The
cleared supernatant was transferred to spin columns con-
taining agarose resin conjugated with 20 μg of specified
antibodies. Incubation was done overnight at 4°C, with
gentle rocking. For control co-IP, lysates were added to
spin columns containing agarose resin conjugated to 20 μg
immunoglobulin G (IgG) (Invitrogen, Carlsbad, CA, USA)
and agarose resin alone. The antibody-antigen complexes
were given six washes with lysis buffer and eluted by incu-
bating the antigen-antibody complex with 50 μl low pH
elution buffer provided in the kit. The eluates were resus-
pended in SDS sample buffer, boiled for 3 min and ana-
lyzed by SDS-PAGE and subsequent western blots.
Pharmacological chemicals inhibitors/activators
Pharmacological chemicals used in this study include
AMPK activator A769662 (100 μM [24], University of
Dundee, UK), AMPK inhibitor Compound C (6-[4-(2-
piperidin-1-ylethoxy-phenyl)]-3-pyridin-4-yl-pyrrazolo
[1,5-a]-pyrimidine (10 μM [25], Calbiochem) and LY294002
(10 μM [26], Cell Signaling Technology). Absolute di-
methyl sulfoxide (DMSO; Calbiochem) was used as solv-
ent to make stock solutions, which were typically diluted
1:1000 to obtain working dilutions; identical concentration
of DMSO was used as vehicle control. Pharmacological
agents were typically replenished every three days.
RNAi-mediated knockdown experiments
Primary HMECs were transfected with Accell small inter-
fering RNA (siRNA) oligos (GE Healthcare Dharmacon,
Little Chalfont, UK) targeting AMPK α2 and PEA15 as
per the manufacturer’s protocol; nontargeting pool siRNA
(GE Healthcare Dharmacon) was used as control siRNA.
Breast cancer cell lines were transfected with specific
siRNA oligos targeting AMPK α2 and PEA15 (Cell Sig-
naling Technology); universal negative siRNA (Sigma-
Aldrich) was used as control. Adherent Michigan Cancer
Foundation 7 breast cancer cell line (MCF7) and breast
cancer cell line derived from metastatic site (pleural effu-
sion) (MDAMB231) were transfected with 20 nM siRNA
using oligofectamine (Invitrogen). After 48 hrs of siRNA
transfection, the cells were trypsinized and seeded in
methylcellulose for further experimentation. AMPK α2
knockdown stable cells were generated by transfecting
MDAMB231 and BT 474 cells with a pool of four short
hairpin RNA (shRNA) constructs targeting AMPK α2
(pRFP-C-RS-PRKAA2) or scrambled (HuSH-29 shRNA
vectors; (Origene Technologies, Rockville, MD, USA)
using Lipofectamine-2000 (Invitrogen). Stable cells were
generated using puromycin (0.5 μg/ml) selection followed
by flow cytometer-based sorting (MoFlo; Beckman Coulter,
Brea, CA, USA) for RFP expression (encoded by the vector)
and were expanded and frozen for future use. Knockdown
was confirmed by immunoblotting.
Figure 1 Mammospheres show elevated AMP-activated protein kinase (AMPK) activity. (A) Phase-contrast microscopic images (left) of
freshly isolated primary human mammary epithelial cells (HMECs) cultured for a week as monolayers in adherent (ADH) condition in regular tissue
culture (TC) dishes, or as mammospheres (MS) in suspension in ultra-low attachment plates (UL plates); magnification ×200. Experimental
strategies (right) involving HMECs seeded in suspension (also see Methods). (B and C) Primary HMECs cultured in ADH condition or in suspension
as MS were harvested at the end of a week and subjected to immunoblot analyses for the specified proteins. Graphs represent densitometry
analyses of western blots to quantify phosphoprotein relative to total protein. Error bars represent standard error of the mean (SEM), (n = 6).
The phosphorylated (p)AMPK antibody recognizes both AMPK α1 and α2 isoforms; antibodies against total AMPK recognize both α1/2 together,
or only individual isoforms α1 or α2; α-tubulin served as loading control for all western blot experiments. (D) Primary HMECs were cultured in UL
plates in the presence of 10 μM AMPK inhibitor, Compound C (CC); dimethyl sulfoxide (DMSO) served as vehicle control. Two days after
treatment, a quarter of the cells were harvested and subjected to immunoblot analyses for specified proteins, while the rest were scored for total
number of MS formed at the end of a week (graph). Error bar represents SEM, (n = 4). (E). Primary HMECs seeded in UL plates were transfected
with control small interfering RNA (siRNA) or siRNA targeting AMPK α2 (Dharmacon, Thermo Fisher Scientific, Waltham, MA, USA). Two days
posttransfection, a quarter of the cells were harvested and subjected to immunoblot analyses for the specified proteins, while the rest were
scored for total number of MS formed at the end of a week (graph). Error bars represent SEM; n = 4.
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methylcellulose
Lentiviruses were generated as described previously [27].
In brief, HEK293T cells were transfected with pCSCG len-
tiviral vectors encoding for wild-type (WT) and S116A
mutant of PEA15 along with packaging vectors: pCMV-
VSVG and pHRΔ8.2. HMECs seeded in 6-well UL attach-
ment plates were spin-infected with viral supernatant in
the presence of protamine sulphate (8 μg/ml). Two days
following infection, a quarter of the cells were harvested
for immunoblot analyses for the specified proteins and the
remaining cells were counted and subjected to mammo-
sphere formation in methylcellulose (as described for can-
cer spheres below). Mammospheres formed by GFP
(encoded by the CSCG vector) positive cells were scored
at the end of seven days.
In vitro kinase assay
One microgram of purified PEA15 (Abcam, Cambridge,
UK) was incubated in the presence or absence of 1 μg of
AMPK heterotrimer (Cell Signaling Technology) for 30
min at 30°C in AMPK kinase buffer (Cell Signaling
Technology) supplemented with 50 μM ATP and 0.1
mM AMP (Sigma-Aldrich). Reactions were terminated
by the addition of SDS sample buffer, resolved by SDS-
PAGE and analyzed by western blotting using phosphor-
ylated (p)PEA15 Ser116 and total PEA15 antibodies. For
radioactive in vitro kinase assay, 1 μg of purified PEA15
was incubated in the presence or absence of 1 μg of
AMPK heterotrimer along with (γ32P) ATP (0.3 μCi) for
30 min at 30°C in AMPK kinase buffer (Cell Signaling
Technology) supplemented with 50 μM ATP and 0.1
mM AMP. Reactions were terminated by the addition of
SDS sample buffer. The product of the kinase assay was
resolved by SDS-PAGE, the gel was dried exposed to a
phosphoimager screen (GE Healthcare) for 4 hrs and
scanned using a Typhoon 9210 scanner (GE Healthcare).
Cell culture, plasmids, transfections, and stable cell lines
Breast cancer cell lines MCF7, BT474 and MDAMB231,
and HEK 293 T (from the American Type Culture Col-
lection (ATCC)) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS) and maintained in standard 5% CO2 incu-
bator at 37°C. Authenticity of the cell lines used was
evaluated and verified by Bio-Synthesis, Inc. (Lewisville,
TX, USA) employing genotyping of 15 short tandem re-
peat (STR) loci and the amelogenin gene (AMEL), and
comparison with genotype information at the ATCC.
The myc-tagged human AMPK α2 pCMV-Tag 3B used
in immunoprecipation experiments was a kind gift from
Ronald Evans. Flag-tagged WT and S116A mutant of
PEA15 were a kind gift from Dr. W. Roth. These were
subcloned into the EcoR1 site of the CSCG lentiviralvector, and protein expression confirmed by western
blotting. MCF7 cells were transiently transfected with
CSCG-PEA15 constructs using Lipofectamine-2000 and
seeded in methylcellulose to assess for sphere forma-
tion. MDAMB231 and BT474 stable cell lines expressing
CSCG-WT or S116A mutant PEA15 were made by two
rounds of GFP (encoded by the CSCG vector) sorting in
MoFlo (Beckman Coulter, Danvers, MA, USA) and these
stable cells were used for in vitro sphere formation experi-
ment and in vivo tumorigenicity experiments.
Sphere formation in methylcellulose
Primary HMECs infected with CSCG-PEA15 constructs
were trypsinized, counted and resuspended in a 1.5%
slurry of methyl cellulose (in DME-F12 supplemented
with growth factors) and plated on 0.6% noble agar-
coated plates at a density of 1 × 105 cells/35 mm dish
and grown for seven days.
Adherent MCF7 and MDAMB231 cells were trypsi-
nized, counted and resuspended in a 1.5% slurry of methyl
cellulose (in DMEM supplemented with 20% FBS) and
plated on 0.6% noble agar-coated plates at a density of 1 ×
105 cells/35 mm dish and grown for seven days. For can-
cer sphere counting, total number of spheres per 20 fields
was counted under a 10× phase contrast microscope. For
immunoblotting experiments, cells were retrieved from
methylcellulose by diluting with phosphate-buffered saline
(PBS), centrifuged, and then lysed in western lysis buffer.
Tumor formation
All animal experiments were reviewed and approved by
the Institutional Animal Ethics committee of the Indian In-
stitute of Sciences, Bangalore. Five-week-old athymicnu/nu
female nude mice were used to undertake subcutaneous
injections of 1 × 106 cells in each flank. Six mice were
assigned for each experiment. Tumor size was measured
every week using digital vernier calipers up to seven weeks.
Tumor volume was calculated using the formula 4/3πr3.
Statistical analysis
All statistical analysis was performed using GraphPad
Prism 5.0 software (GraphPad, La Jolla, CA, USA). All
data are presented as mean ± standard error of the mean
(SEM). P values <0.05 were considered to be statistically
significant. Statistical analysis was done using paired
Student’s t test; ***represents P <0.001, **represents P <0.01
and *represents P <0.05.
Results
Mammosphere formation requires AMPK activity
In order to understand the signaling mechanisms that
facilitate MS formation by normal HMECs, we first ex-
amined the status of the AMPK pathway, which has re-
cently been implicated in anoikis resistance [15,16],
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freshly isolated normal HMECs were cultured for a week
in serum-free media in regular tissue culture dishes,
leading to the generation of ADH cultures (Figure 1A).
In parallel, HMECs were cultured for a week in UL at-
tachment plates that prevent attachment (also referred
to as suspension culture), leading to the generation of
floating MS (Figure 1A; also see Methods). Immunoblot
analysis of cells harvested at the end of a week from
both the conditions revealed a significant increase in the
levels of Thr172 phosphorylated, active forms of AMPKα
in MS compared to ADH HMECs; levels of total
AMPKα remained unaltered (Figure 1B). In addition,
MS showed increased phosphorylation of ACC and
Raptor, two well-established targets of AMPK [11],
compared to adherent HMECs (Figure 1C). Thus, these
data revealed increased activation of AMPK in MS com-
pared to ADH HMEC cultures.
We next investigated the significance of AMPK activa-
tion in mammosphere formation. To do so, HMECs were
cultured in UL attachment plates for a week in the pres-
ence of a pharmacological inhibitor of AMPK, Compound
C, a potent reversible inhibitor that is competitive with
ATP [28]. Compared to treatment with DMSO (vehicle
control), treatment with Compound C led to a decrease in
the levels of pACC, confirming the efficacy of the inhibi-
tor, as well as impaired MS formation (Figure 1D), sug-
gesting that AMPK activation may be required for MS
formation. To further confirm this, we undertook RNA
interference (RNAi)-mediated silencing of AMPK expres-
sion. HMECs express both α1 and α2 isoforms of AMPK;
however, we detected several fold higher expression of α2
compared to α1 (Figure S1A in Additional file 1). Accord-
ingly, we chose to knockdown AMPK α2 expression using
the RNAi approach. Transfection of HMECs cultured in
UL attachment plates with siRNA oligos targeting AMPK
α2 led to an approximately 80% reduction in the protein
levels of AMPK α2 compared to control siRNA trans-
fections (Figure 1E). Knockdown of AMPK α2 did not
significantly alter the levels of AMPK α1 expression
(Figure S1B in Additional file 1). Further, transfection of
AMPK α2 siRNA led to an approximately 80% re-
duction in AMPK activity, as gauged by a reduction in
pACC levels (Figure 1E). Importantly, knockdown of
AMPK α2 also impaired MS formation (Figure 1E). An
independent set of shRNA constructs targeting AMPK
α2 also yielded similar results (Figure S1C in Additional
file 1). Taken together, these results revealed the re-
quirement of AMPK signaling for MS formation by nor-
mal HMECs.
AMPK activation inhibits apoptosis
We next investigated how AMPK activation might facilitate
the anchorage-independent growth of MS. Detachment ofepithelial cells from the matrix triggers ‘anoikis’, a form of
apoptosis [3,4]. Consistent with this, HMECs seeded in UL
attachment plates showed an increase in the levels of apop-
totic markers (such as cleaved caspase-3, cleaved PARP, and
cleaved caspase-8) by day 2 of suspension culture compared
to adherent HMECs (Figure 2A). However, from days 2 to
6 in suspension culture, there was a gradual decrease in
apoptosis (Figures 2A and Figure S2A in Additional file
2), indicative of anoikis-resistant outgrowth of MS from
a subset of HMECs. Further, we noticed an increase in
cleaved caspase-8 in HMECs seeded in suspension
(Figure 2A), and inhibition of caspase-8 led to an in-
crease in MS formation (Figure S2B in Additional file 2),
suggesting the possible involvement of the death receptor
pathway in anoikis [29]. To investigate the role of AMPK
in MS formation, we assessed the effects of AMPK activa-
tion and inhibition on the status of apoptosis in HMECs
cultured in UL attachment plates for a week. Compared to
vehicle control DMSO, treatment with an AMPK activator
A769662 [30], which directly activates the heterotrimeric
form of AMPK both allosterically and by inhibiting de-
phosphorylation [31], led to an increase in pACC levels,
while treatment with the AMPK inhibitor Compound C
led to a decrease in pACC levels, thus confirming the effi-
cacy of the pharmacological agents (Figure 2B). Further,
treatment with A769662 led to a reduction in the apoptotic
readouts compared to DMSO vehicle treatment (Figure 2B).
This is also consistent with the observed increase in the
number of MS generated upon A769662 treatment (data
not shown). On the other hand, treatment with Compound
C led to an increase in the apoptotic readouts (Figure 2B),
which was also consistent with the observed impairment
of MS formation (Figure 1D). Further, transfection of
HMECs seeded in UL attachment plates with AMPK
siRNA, which was previously shown to impair MS
formation (Figure 1E), also revealed an increase in the
apoptotic readouts (Figure 2C). Together, these data
suggested that AMPK activation in suspension might
facilitate MS formation by inhibiting matrix deprivation-
induced apoptosis.
AMPK activation leads to increased PEA15 Ser116
phosphorylation
We next investigated the mechanisms downstream of
AMPK activation that might be involved in the inhib-
ition of apoptosis in matrix-deprived HMECs. Phosphor-
ylation of PEA15 at Ser116 residue has been shown to
block apoptosis by associating with FADD and interfer-
ing with the assembly of the death-inducing signaling
complex (DISC) [32]. Since this phosphorylation has re-
cently been shown to inhibit apoptosis under the stress
of glucose deprivation [23], we investigated the status of
PEA15 phosphorylation in HMECs subjected to matrix
deprivation using an antibody that specifically recognizes
Figure 2 AMP-activated protein kinase (AMPK) inhibits apoptosis through phosphoprotein enriched in astrocytes 15 kDa (PEA15)
phosphorylation. Primary human mammary epithelial cells (HMECs) cultured under following conditions were harvested and subjected to
immunoblot analysis for the specified proteins: (A) HMECs seeded in adherent (ADH) condition for six days or in suspension (in ultra-low (UL)
plates) for two, four or six days; n = 3. (B) HMECs seeded in suspension in the presence of 100 μM AMPK activator (A769662), 10 μM AMPK
inhibitor (Compound C) or dimethyl sulphoxide (DMSO) (vehicle control) for a week; n = 3. (C) HMECs seeded in UL plates and transfected with
control small interfering RNA (siRNA) or siRNA targeting AMPK α2 (Dharmacon) were harvested after one week; n = 4. (D) HMECs seeded in ADH
condition or in suspension in UL plates for a week. Graph represents densitometric analysis of western blots to quantify phospho PEA15 Ser116
relative to total PEA15. Error bars represent standard error of the mean (SEM); (n = 6). (E) HMECs seeded in UL plates for 24 hrs and treated with
DMSO (vehicle control), 100 μM AMPK activator (A769662), or 10 μM AMPK inhibitor (Compound C) for a period of 2 hrs; n = 3. (F) HMECs seeded
in UL plates and treated with increasing amounts of AMPK inhibitor Compound C, in the presence of a constant amount of AMPK activator
A769662, for 2 hrs; n = 3. (G) HMECs seeded in UL plates and transfected with control siRNA or siRNA targeting AMPK α2 and harvested two days
following transfection; n = 4. (H) HMECs seeded in UL plates and transfected with control siRNA or siRNA targeting AMPK α2 were treated with
100 μM AMPK activator (A769662) after two days following transfection for 2 hrs and harvested, n = 3.
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vealed an increase in Ser116 phosphorylation of PEA15 in
MS concomitant with AMPK activation (as gauged by
pAMPK Thr172 levels) (Figure 2D). Since only the double
phosphorylated form of PEA15 (at residues Ser104 and 116)
is associated with anti-apoptotic functions, we investigated
the status of Ser104 phosphorylation in HMECs. Although
Ser104 was phosphorylated in MS, there was no significant
difference in its levels between ADH HMECs and MS
(Figure 2D). The total PEA15 under these two conditions
remained unchanged (Figure 2D). Thus, these data re-
vealed an increase in Ser116 phosphorylation of PEA15 in
MS compared to ADH HMECs.
To investigate the role of AMPK in this process, we
investigated the effects of AMPK activation and inhib-
ition on the status of PEA15 Ser116 phosphorylation. To
do so, we treated HMECs seeded in UL attachment
plates with pharmacological activator or inhibitor of
AMPK and measured the levels of pPEA15 Ser116 by
immunoblotting. Compared to DMSO (vehicle)-treated
cells, while activation of AMPK with A769662, as mea-
sured by an increase in pACC levels, led to an increase
in pPEA15 Ser116 levels, inhibition of AMPK by Com-
pound C, as measured by a decrease in the levels of
pACC, led to a decrease in pPEA15 Ser116 levels in
these cells (Figure 2E), suggesting the involvement of
AMPK upstream of PEA15 Ser116 phosphorylation.
Moreover, when HMECs seeded in UL attachment plates
were treated with increasing concentrations of Com-
pound C in the presence of a constant amount of
A769662, we observed a Compound C dose-dependent
decrease in the levels of pPEA15 Ser116 in parallel with
that of pACC (Figure 2F), indicating the specificity of
PEA15 Ser116 phosphorylation to AMPK activation.
To further confirm the involvement of AMPK upstream
of PEA15 phosphorylation, we assessed the effects of
AMPK knockdown. Transfection of AMPK α2 siRNA into
HMECs seeded in UL attachment plates led to a reduction
in the levels of pPEA15 Ser116 and pACC compared to
control siRNA transfections (Figure 2G). Additionally, in
the presence of AMPK α2 siRNA, pharmacological activa-
tion of AMPK with A769662 failed to restore PEA15
Ser116 phosphorylation (Figure 2H), further supporting an
AMPK-dependent phosphorylation of PEA15 Ser116 in
MS. Furthermore, inhibition of Akt and CaMKII, two
known upstream kinases of PEA15 [33], failed to affect
PEA15 Ser116 phosphorylation in suspension (Figure S2
C-E in Additional file 2). In addition, co-IP experiments
revealed increased association of pPEA15 Ser116 with
FADD upon AMPK activation, while its inhibition re-
duced this association (Figure S2F in Additional file 2).
Taken together, these data suggested a role for Ser116
phosphorylated PEA15 downstream of AMPK activation
in the inhibition of apoptosis during MS formation.PEA15 and its phosphorylation at Ser116 are critical for
mammosphere formation
To understand the significance of PEA15 and its phos-
phorylation in the inhibition of apoptosis and MS forma-
tion, we investigated the effects of PEA15 knockdown.
Transfection of HMECs cultured in UL attachment plates
with PEA15 siRNA led to approximately 90% decrease in
the levels of total PEA15 in these cells (Figure 3A). Con-
sistent with this, these cells also showed reduced levels of
pPEA15 Ser116 (Figure 3A). Further, transfection with
PEA15 siRNA led to an increase in apoptosis, as detected
by increased levels of cleaved PARP and cleaved caspase-8
(Figure 3A), and also impaired MS formation (Figure 3A),
together revealing the requirement of PEA15 in MS
formation.
We next investigated the role of Ser116 phosphorylation
of PEA15 in MS formation. To do so, we undertook
lentiviral-mediated expression of the S116A nonphosphor-
ylatable mutant of PEA15 in HMECs cultured in UL
attachment plates. Compared to empty vector and WT-
PEA15-transduced HMECs, those transduced with PEA15
S116A mutant had reduced levels of pPEA15 Ser116,
and were also impaired in their MS-forming potential
(Figure 3B). Thus, these data revealed the importance
of PEA15 and its phosphorylation on Ser116 for MS
formation.
AMPK directly phosphorylates PEA15
Since our data revealed an AMPK-dependent phosphoryl-
ation of PEA15 in MS, we next investigated if PEA15
could be a direct substrate for AMPK. The kinetics of
PEA15 Ser116 phosphorylation following AMPK activation
paralleled that of two well-established substrates of
AMPK, ACC (Figure 2F) and Raptor [34] (Figure 3C), sug-
gesting that PEA15 could be a direct target for AMPK.
Clustal W alignment revealed that four out of eight resi-
dues flanking Ser116 in PEA15 (Figure S3A in Additional
file 3) showed a significant match with the AMPK consen-
sus motif [34,35]. We also found that the PEA15 Ser116
flanking sequences are highly conserved among mammals
and it matches with the already characterized AMPK
phosphorylation sites in various substrates (Figure S3B
and C in Additional file 3). These analyses suggested that
PEA15 could be a substrate for AMPK. To assess this, we
first gauged if the two proteins interacted. Co-IP assays
undertaken with MS lysates and MCF7 cells expressing
myc-tagged AMPK revealed association of AMPK with
PEA15 (Figure 3D and Figure S3D in Additional file 3).
We then assessed if AMPK can directly phosphorylate
PEA15. To do so, we undertook in vitro kinase assays
with commercially procured PEA15 and active hete-
rotrimeric form of AMPK proteins. Subsequent im-
munoblot analysis using an antibody that specifically
recognizes PEA15 phosphorylated at Ser116 residue
Figure 3 Phosphoprotein enriched in astrocytes 15 kDa (PEA15) is a novel AMP-activated protein kinase (AMPK) substrate. (A) Primary
human mammary epithelial cells (HMECs) cultured in ultra-low (UL) plates were transfected with control small interfering RNA (siRNA) or siRNA
targeting PEA15. Two days posttransfection, a quarter of the cells were harvested and subjected to immunoblot analysis for the specified proteins
(i), while the rest were scored for total number of mammospheres (MS) formed at the end of a week (ii). Error bars represent standard error of
the mean (SEM); n = 4. (B) Primary HMECs cultured in UL plates were infected with control (empty vector) CSCG lentivirus, or those encoding for
PEA15-WT or PEA15-S116A mutant with similar infection efficiencies (as scored by GFP-positive cells). Two days following infection, 1 × 105
transduced cells were seeded in methylcellulose and total number of GFP-positive mammospheres formed was counted at the end of a week.
Error bars represent standard error of the mean (SEM); n = 3. (C) Primary HMECs seeded in UL plates were treated with AMPK activator A769962
(100 μM) for 0 min, 30 min, 1 hr and 2 hrs, and subjected to immunoblot analysis for the specified proteins; n = 3. (D) Primary HMECs seeded
in UL plates were subjected to immunoprecipitation with total AMPK antibody followed by immunoblotting for specified proteins. Rabbit
immunoglobulin G (IgG)-treated lysate and resin alone served as controls, n = 3. (E) Commercially procured heterotrimeric AMPK and pure PEA15
were incubated in an in vitro kinase assay buffer in the presence of 50 μM adenosine triphosphate (ATP) and 0.1 mM AMP for 30 min, and then
subjected to immunoblot analyses with commercially available antibodies that specifically recognize PEA15 Ser116 phosphorylation; total PEA15
antibody served as a loading control. (F) Autoradiography of in vitro kinase assay using pure AMPK and PEA15 proteins performed in the presence
of γ32P-labeled ATP (0.3 μCi) for 30 min; n = 3.
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presence of active AMPK (Figure 3E). In addition, in vi-
tro kinase assays performed in the presence of [γ32P]
ATP also confirmed direct phosphorylation of PEA15
by AMPK (Figure 3F). Thus, these results revealed that
PEA15 could indeed be a novel target of AMPK.
Taken together, these data revealed that activation of
AMPK and phosphorylation of PEA15 at Ser116 facilitates
MS formation by inhibiting apoptosis. Our study thus iden-
tifies a novel AMPK-PEA15 axis in the anoikis-resistant
outgrowth of a subset of normal HMECs as MS.AMPK-PEA15 axis is critical for the anchorage-
independent growth of breast cancer cells
Since anchorage-independent growth is a fundamental
property of solid tumors, we next investigated if the
AMPK-PEA15 axis played any role in the tumorigenicity
of breast cancer cells. For this, we first compared the
status of AMPK and PEA15 signaling in MCF7 and
BT474 breast cancer cell lines grown as ADH monolayer
cultures or as cancer spheres in methylcellulose (Figure
S4A in Additional file 4; also see Methods). Immunoblot
analysis revealed a significant increase in the levels of
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(Figure 4A), indicating activation of AMPK pathway in
matrix-deprived cancer cells, consistent with recent re-
ports [15,17]. Compared to ADH cultures, cells growing
as cancer spheres also showed an increase in the levels
of pPEA15 Ser116 (Figure 4A); levels of total PEA15 did
not show any significant difference. Primary breast
cancer-derived cells also showed elevated AMPK activity
and pPEA15 Ser116 levels compared to those growing in
ADH condition (Figure 4A). Thus, similar to HMECs,
breast cancer cells also showed an increase in AMPK ac-
tivity and PEA15 Ser116 phosphorylation upon matrix
deprivation (Figure S4B in Additional file 4), suggesting
the possible involvement of an AMPK-PEA15 axis in the
survival of matrix-deprived breast cancer cells too.
We next investigated the requirement of AMPK in the
anchorage-independent growth of breast cancer cells as
spheres. Treatment with AMPK inhibitor Compound C
(Figures 4B, and Figure S4C and D in Additional file 4)
or knockdown of AMPK α2 (Figures 4C and Figure S4
E-G in Additional file 4) dramatically decreased sphere
formation in MCF7, MDAMB231 and BT 474 breast
cancer cell lines. Further, inhibition or knockdown of
AMPK also impaired PEA15 Ser116 phosphorylation in
these cells (Figure 4B and C, Figure S4 C-E in Additional
file 4), and increased apoptosis, as revealed by increased
PARP levels (Figure 4C and Figure S4E in Additional file 4).
Thus, these data revealed the requirement of AMPK
activation for sphere formation by breast cancer cells.
We next assessed the importance of PEA15 and its
phosphorylation downstream of AMPK activation in the
anoikis-resistant growth of breast cancer cells. Com-
pared to control siRNA, transfection with PEA15 siRNA
led to reduced sphere formation (Figure 4D), which
could not be rescued by pharmacological activation of
AMPK (Figure 4E). Furthermore, overexpression of the
nonphosphorylatable S116A mutant of PEA15 also dra-
matically decreased sphere formation in all the three cell
lines compared to WT PEA15 (Figure 4F, and Figure S4 H
and I in Additional file 4). In addition, overexpression
of PEA15 S116A mutant led to increased apoptosis, as
detected by cleaved PARP levels (Figure 4F), which
was also not rescued by pharmacological activation of
AMPK (data not shown). Thus, these set of experiments
highlighted the importance of PEA15 and its phosphor-
ylation at Ser116 in breast cancer sphere formation.
We further gauged the importance of AMPK activation
and PEA15 Ser116 phosphorylation in its association with
FADD in breast cancer cells. We observed increased as-
sociation of pPEA15 Ser116 with FADD under conditions
of AMPK activation (Figure 4G). Also, compared to WT
PEA15-expressing cells, those expressing the PEA15
S116A mutant showed less association of PEA15 with
FADD (Figure 4H) highlighting the importance of Ser116phosphorylation of PEA15 for its association with FADD
in these cells, in keeping with previous reports [22,36]. To-
gether, these experiments revealed the importance of the
AMPK-PEA15 axis in the inhibition of apoptosis during
the anchorage-independent growth of breast cancer cells
in vitro.
We next investigated the relevance of the AMPK-PEA15
signaling axis in the tumorigenicity of breast cancer cells
in vivo. To do so, MDAMB231 cells transiently transfected
with control or AMPK α2 siRNA were injected subcutane-
ously into either flanks of immunocompromised mice.
Knockdown of AMPK (Figure S5A in Additional file 5) led
to impairment of tumor formation compared to control
siRNA transfections (Figure 5A). Tumor formation was also
impaired in MDAMB231 and BT 474 cells stably expressing
shRNA constructs targeting AMPK α2 (Figure 5B and C).
Further, MDAMB231 and BT 474 cells stably expressing
the nonphosphorylatable mutant of PEA15 were also
markedly impaired in their tumor-forming potential com-
pared to WT PEA15-expressing cells (Figure 5C and D),
together suggesting that AMPK activation and PEA15
phosphorylation are both necessary for tumor formation
by breast cancer cells.
Thus, our study uncovers a hitherto unknown AMPK-
PEA15 signaling axis in the context of anoikis-resistant
growth of normal and cancerous mammary epithelial cells,
suggesting that targeting this axis could serve as a novel
strategy to curb cancer cell dissemination and metastasis.
Discussion
Anoikis is a physiologically relevant process, which plays
an important role in normal development as well as in the
maintenance of tissue homeostasis throughout adult life.
By preventing detached epithelial cells from colonizing
elsewhere, anoikis serves as a barrier to cancer progres-
sion. Thus, acquisition of anoikis resistance is considered
to be a prerequisite for solid tumor metastasis. Hitherto
considered a fundamental property of cancer cells, how-
ever, recent studies have intriguingly identified the anoikis-
resistant outgrowth of a small subset of normal epithelial
cells as floating spheroids in vitro in multiple epithelial sys-
tems including the mammary, prostate, and salivary gland
[7,37,38]. Thus, it is conceivable that epithelial cancer cells
exploit mechanisms already inherent within their normal
counterparts for survival in circulation. In this study, we
have identified a novel AMPK-PEA15 axis that confers
survival signals to facilitate the anchorage-independent
growth of normal HMECs as MS. We further show that
the same axis plays a critical role in the anchorage-
independent growth of breast cancer cells both in vitro
and in vivo.
Though our study has identified a role for AMPK in
the anchorage-independent growth of normal HMECs as
mammospheres in vitro, the in vivo relevance of this
Figure 4 AMP-activated protein kinase (AMPK)-phosphoprotein enriched in astrocytes 15 kDa (PEA15) axis is critical for the anchorage-
independent growth of breast cancer cells. (A) Michigan Cancer Foundation 7 breast cancer cell line (MCF7), BT-474, and primary breast
cancer-derived cells cultured in adherent (ADH) condition or as cancer spheres (CS) for a week were harvested and subjected to immunoblotting;
n = 3. (B) MCF7 cells cultured in methylcellulose for a week in the presence of 10 μM AMPK inhibitor Compound C or dimethyl sulphoxide (DMSO)
(vehicle control) were subjected to immunoblotting. Graph represents number of spheres formed/20 fields. Error bars represent standard error of the
mean (SEM); n = 3. (C-F) Adherent MCF7 breast cancer cells were transfected with specified small interfering RNA (siRNA) oligos/plasmids (see below).
Two days posttransfection, 1 × 105 cells/35 mm dish were seeded in methylcellulose. After 48 hrs, cells were retrieved from some dishes and subjected
to immunoblot analyses for the specified proteins. Parallel dishes were allowed to form spheres; graph represents sphere formation at the end of a
week, error bar represents SEM: (C) control siRNA or siRNA targeting AMPK α2, n = 4; (D) control siRNA or siRNA targeting PEA15, (n = 4); (E) control
siRNA or siRNA targeting PEA15 and seeded in methylcellulose in the presence of 100 μM AMPK activator, A769662; DMSO served as vehicle control,
n = 4; (F) transfected with CSCG constructs expressing flag-tagged wild-type (WT) or S116A mutant of PEA15, n = 4. (G) MDAMB231 cells were treated
with DMSO or 100 μM AMPK activator, A769662, and immunoprecipitated with anti-Fas-associated death domain protein (FADD) antibody. The
immunoprecipates were resolved by SDS-PAGE followed by immunoblotting for specified proteins, n = 3. (H) BT 474 cells stably expressing
flag-tagged WT-PEA15 or PEA15-S116A mutant were seeded in methyl cellulose for two days, retrieved and immunoprecipitated with anti-flag
antibody. The immunoprecipitates were resolved by SDS-PAGE followed by immunoblotting for specified proteins, n = 3.
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Figure 5 AMP-activated protein kinase (AMPK)-phosphoprotein enriched in astrocytes 15 kDa (PEA15) axis is critical for tumorigenicity
of breast cancer cells. (A) Breast cancer cell line derived from metastatic site (pleural effusion) (MDAMB231) cells were transfected with control
small interfering RNA (siRNA) or siRNA targeting AMPK α2 and injected subcutaneously (1 × 106 cells/injection) into six nude mice (control siRNA
transfected cells in the left flank, and AMPK α2 siRNA-transfected cells in the right flank) and monitored for tumor formation for seven weeks.
(B and C) MDAMB231 cells (B) and BT 474 cells (C) stably expressing short hairpin RNA (shRNA) pool against AMPK α2 or scrambled shRNA were
introduced subcutaneously (1 × 106 cells/injection) into three nude mice and tumor formation was monitored for the indicated time period.
Control shRNA-expressing cells were injected in the left flank, and AMPK α2 shRNA-expressing cells in the right flank. Tumors were resected and
tumor-derived cells subjected to immunoblotting for specified proteins. (D and E) MDAMB231 cells (D) and BT 474 cells (E) stably expressing
CSCG-WT-Flag PEA15 or CSCG-S116A-Flag-PEA15 were injected subcutaneously (1 × 106 cells/injection) into six nude mice and tumor formation
was monitored for the indicated time period. Cells stably expressing wild-type (WT)-PEA15 were injected in the left flank, while cells stably
expressing S116A-PEA15 were injected in the right flank. Tumors were resected and tumor-derived cells subjected to immunoblotting for
specified proteins.
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homeostasis remains unclear at this point of time.
Mammary cells, like most epithelial cells, grow attached
to the basement membrane in vivo. In vitro, adhesion
promotes differentiation, while the nonadherent MS are
enriched in stem/progenitor cells [7]. Such undifferenti-
ated cells in vivo may reside in niches lacking proper
ECM attachment, and may employ survival signals ema-
nated by AMPK activation. Furthermore, during post-
lactational involution, mammary cells undergo massive
apoptosis thought to be triggered by the degradation of
the ECM [39]. Regrowth of the mammary gland during
the next pregnancy is believed to be due to leftover
stem/progenitor-like cells [40] that may utilize AMPK
signaling for their survival. However, no mammary
phenotype has so far been reported in mice lacking
AMPK α 1 or 2; double knockout (KO) mice are embry-
onically lethal [37]. Perhaps, the presence of one isoform
may have compensated for the other since mammary cells
express both the AMPK α isoforms. Thus, the generation
of conditional, mammary gland-specific AMPK α 1 + 2
KO mice might reveal important information on the role
of AMPK in the development and maintenance of the
adult mammary gland. Further, the presence of a small
population of cells with the capability of anoikis-resistant
growth within the normal mammary gland implies that
these cells could be targets for oncogenic events leading to
luminal filling and breast carcinogenesis. Indeed, we re-
cently showed that the tumorigenic transformation of
MS-derived cells led to the generation of invasive ductal
carcinoma harboring cancer stem-like cells [27].
The role of AMPK in the context of cancer has
remained controversial, with earlier studies implicating a
tumor-suppressive role for the LKB1-AMPK axis, while
recent studies unfurling tumor-promoting roles [41]. For
example, the AMPK upstream kinase LKB1 is a tumor
suppressor that is mutated in Peutz-Jegher syndrome
[11]. Additionally, AMPK has been shown to regulate
the activity of p53 and pRb leading to the inhibition of
cancer cell growth [42,43]. In contrast, AMPK has been
demonstrated to trigger adaptive responses in cancercells under metabolically depressed states like hypoxia and
low glucose conditions [14,44]. Additionally, AMPK has
been shown to confer resistance to human glioma and
mouse fibrosarcoma cells upon cisplatin treatment [45].
Indeed, several kinds of stresses associated with tumor
progression, including hypoxia, nutrient deprivation and
reactive oxygen species, are known triggers that activate
AMPK. In this study, we show that the stress of anchorage-
deprivation leads to AMPK activation and this is required
for the anchorage-independent growth of breast cancer
cells. Our data is consistent with two recent studies that
have associated AMPK with matrix detachment [17,46]. Of
note, when matrix-deprived cancer cells reattach, AMPK
activity gradually decreases to basal level (data not shown).
Thus, AMPK activation might serve as a reversible switch
in cancer cell dissemination and metastasis.
Upon activation, AMPK brings about energy homeosta-
sis by inhibiting anabolic pathways and activating catabolic
pathways [47,48]. In line with this, one study showed the
maintenance of NADPH homeostasis as a predominant
mechanism by which AMPK enables cancer cell survival
during stress conditions and promotes tumor formation
[17]. In another study, AMPK-mediated mTORC1 inhib-
ition and suppression of protein synthesis as a means for
bioenergetic conservation was implicated in anoikis resist-
ance [15]. In our study, we show that AMPK activation
leads to Ser116 phosphorylation of PEA15 that promotes
its association with FADD, thereby protecting matrix-
deprived cells from apoptosis. Thus, pleiotropic effects
downstream of AMPK activation are likely to contribute
to anoikis resistance. Earlier studies had implicated a role
for PI3K/Akt, epidermal growth factor receptor (EGFR)
activation, and Bcl-2 in the survival of cancer cells under
detachment [49-51]. Thus, stress signaling pathways likes
AMPK might function in concert with these other signal-
ing pathways to enable anchorage-independent survival of
cancer cells.
Signaling by the death-receptor proteins, such as Fas
and TNF-R1, leads to the formation of the death-induced
silencing complex (DISC) consisting of death-receptor,
FADD, and caspase-8 which initiates the caspase cascade
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cated in anoikis [9,29]. Matrix detachment leads to overex-
pression of Fas L and Fas R, while overexpression of
dominant-negative form of FADD inhibits anoikis [9,29].
Further, matrix attachment has been shown to protect
cells from Fas-induced apoptosis, whereas matrix detach-
ment sensitizes cells to Fas-mediated apoptosis [9]. Our
data revealed increased caspase-8 cleavage in matrix-
detached HMECs, while inhibition of caspase-8 led to in-
crease in MS formation. However, how matrix detachment
leads to the activation of the death-receptor pathway in
these cells needs to be further explored.
The PEA15 protein associates with ERK in the cyto-
plasm, restricting its nuclear entry, thus functioning as a
tumor suppressor. However, phosphorylation of PEA15
leads to changes in its binding partners, and converts it
into a tumor promoter [21]. Phosphorylation at the Ser116
position enables its association with FADD, leading to the
disruption of the DISC assembly and blocking apoptosis
[21]. Both Akt and CaMKII have previously been identified
as upstream kinases for PEA15 Ser116 phosphorylation.
However, our study revealed that under matrix-deprived
condition, inhibition of Akt or CaMKII failed to alter the
levels of PEA15 Ser116 phosphorylation in HMECs. InFigure 6 AMP-activated protein kinase (AMPK) activation inhibits ano
(PEA15) Ser116 phosphorylation. Matrix deprivation triggers apoptosis, at
human mammary epithelial cells (HMECs) and breast cancer cells growing
and activation of AMPK that in turn phosphorylates PEA15 at Ser116, thus p
(FADD) and inhibition of apoptosis.contrast, inhibition or knockdown of AMPK impaired this
phosphorylation. Our data further revealed direct phos-
phorylation of PEA15 Ser116 by AMPK, thus identifying
AMPK as an upstream kinase of PEA15. It is plausible that
multiple stress kinases employ similar downstream mecha-
nisms to mediate their functions, and perhaps do so in a
context-dependent manner. Under the stress of matrix
deprivation, our data revealed that AMPK plays a predom-
inant role in the phosphorylation of PEA15. Thus, matrix
detachment may trigger anoikis, at least in part, through
the death-receptor pathway; our data shows that AMPK
activation upon matrix deprivation helps overcome anoikis
by phosphorylating PEA15 at Ser116 position, which asso-
ciates with FADD and blocks apoptosis (Figure 6). Further,
PEA15 phosphorylation at Ser116 was shown to be re-
quired for blocking apoptosis in glucose-deprived glio-
blastoma cells [2]. Since glucose deprivation is known to
activate AMPK [14,52], it is possible that AMPK may be
involved with PEA15 phosphorylation under the stress of
glucose deprivation too. Of note, both AMPK and its con-
sensus motif on PEA15 are conserved across species.
Thus, AMPK-mediated phosphorylation of PEA15 could
be an evolutionarily conserved pro-survival mechanism to
withstand multiple stress conditions.ikis through phosphoprotein enriched in astrocytes 15 kDa
least in part, through the death-receptor pathway. We show that in
in suspension, matrix deprivation leads to increased phosphorylation
romoting its association with Fas-associated death domain protein
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Understanding the molecular mechanisms that contribute
to anoikis resistance is important for designing strategies
to prevent cancer cell dissemination and spread. In this
study, we have uncovered a novel AMPK-PEA15 signaling
axis that contributes to the anoikis-resistant growth of
normal HMECs as MS. We further show that this signal-
ing axis is also critical for the anchorage-independent
growth of breast cancer cells both in vitro and in vivo, sug-
gesting that cancerous breast cells may exploit a mechan-
ism pre-existent within their normal counterparts to their
benefit. Thus, our study reveals targeting the AMPK-
PEA15 axis as a novel therapeutic approach in the preven-
tion of breast cancer dissemination and metastasis.
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